Mainz Biomed N.V. (MYNZ)

$1.75 -0.01 (-0.57%)
Market Cap 8.01M
Revenue (ttm) 890,000.00
Net Income (ttm) -21.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,432.58%
Debt to Equity Ratio 0.18
Volume 64,500
Avg Vol 178,438
Day's Range N/A - N/A
Shares Out 4.58M
Stochastic %K 67%
Beta 0.25
Analysts Sell
Price Target $14.00

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 49 6131 554 2860
Address:
Robert Koch Strasse 50, Mainz, Germany
Orlandotrader
Orlandotrader Aug. 22 at 2:24 PM
$MYNZ Huge wall at 1.90. Knock down this wall Gorbachev!!!!
0 · Reply
Orlandotrader
Orlandotrader Aug. 18 at 2:32 PM
$MYNZ Making our way back to 2$ prior to Sneak Peak Data.
0 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Aug. 13 at 9:32 PM
$MYNZ any news on why this cum stain went up?
0 · Reply
Righon23420
Righon23420 Aug. 13 at 8:12 PM
$MYNZ good day!
0 · Reply
Duskfall
Duskfall Aug. 13 at 4:36 PM
$MYNZ
0 · Reply
Duskfall
Duskfall Aug. 13 at 3:36 PM
$MYNZ Drop this! I want to join under 1.50
0 · Reply
kshonstocks
kshonstocks Aug. 13 at 3:00 PM
$MYNZ off the bottom and 50 dma b/o area
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 13 at 2:47 PM
$MYNZ Mainz Biomed shares are trading higher after the company announced it received Swissmedic approval and is paving the way for a Swiss launch of a non-invasive colorectal cancer test.
0 · Reply
Tbio64
Tbio64 Aug. 13 at 2:13 PM
$MYNZ soon approved in us...and then booom 100$
0 · Reply
BioTuesdays
BioTuesdays Aug. 13 at 2:03 PM
$MYNZ has announced that its non-invasive colorectal cancer (CRC) screening test—ColoAlert—has been registered and approved for distribution by the Swiss regulatory and supervisory authority, Swissmedic. https://biotuesdays.com/2025/08/13/swissmedic-grants-mainz-approval-to-market-coloalert/
0 · Reply
Latest News on MYNZ
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 13, 2025, 8:01 AM EDT - 11 days ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Aug 4, 2025, 10:22 AM EDT - 20 days ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 23, 2025, 8:01 AM EDT - 4 weeks ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jul 15, 2025, 8:01 AM EDT - 5 weeks ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 25, 2025, 8:01 AM EDT - 2 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Jun 10, 2025, 9:01 AM EDT - 2 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 19, 2025, 8:01 PM EDT - 3 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

May 16, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 29, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Apr 28, 2025, 8:01 AM EDT - 4 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 27, 2025, 9:01 AM EDT - 5 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 13, 2025, 8:01 AM EDT - 5 months ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mar 3, 2025, 8:01 AM EST - 6 months ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed Expands into Switzerland with labor team w

Feb 20, 2025, 8:01 AM EST - 6 months ago

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Feb 11, 2025, 8:01 AM EST - 6 months ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 27, 2025, 8:01 AM EST - 7 months ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Jan 21, 2025, 8:01 AM EST - 7 months ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 19, 2024, 8:01 AM EST - 8 months ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 16, 2024, 5:00 PM EST - 8 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 12, 2024, 8:00 PM EST - 9 months ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Dec 3, 2024, 2:40 PM EST - 9 months ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Mainz Biomed Announces Stock Split

Nov 29, 2024, 8:45 AM EST - 9 months ago

Mainz Biomed Announces Stock Split

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 8, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Oct 1, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Mainz Biomed Provides Half Year 2024 Corporate Update

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Mainz Biomed Reports Full Year 2023 Financial Results

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 19, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 12, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mar 5, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 27, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 22, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 21, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Mainz Biomed Provides Year-End Corporate Review 2023

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Dec 19, 2023, 3:39 PM EST - 1 year ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Dec 19, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Dec 12, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Orlandotrader
Orlandotrader Aug. 22 at 2:24 PM
$MYNZ Huge wall at 1.90. Knock down this wall Gorbachev!!!!
0 · Reply
Orlandotrader
Orlandotrader Aug. 18 at 2:32 PM
$MYNZ Making our way back to 2$ prior to Sneak Peak Data.
0 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Aug. 13 at 9:32 PM
$MYNZ any news on why this cum stain went up?
0 · Reply
Righon23420
Righon23420 Aug. 13 at 8:12 PM
$MYNZ good day!
0 · Reply
Duskfall
Duskfall Aug. 13 at 4:36 PM
$MYNZ
0 · Reply
Duskfall
Duskfall Aug. 13 at 3:36 PM
$MYNZ Drop this! I want to join under 1.50
0 · Reply
kshonstocks
kshonstocks Aug. 13 at 3:00 PM
$MYNZ off the bottom and 50 dma b/o area
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 13 at 2:47 PM
$MYNZ Mainz Biomed shares are trading higher after the company announced it received Swissmedic approval and is paving the way for a Swiss launch of a non-invasive colorectal cancer test.
0 · Reply
Tbio64
Tbio64 Aug. 13 at 2:13 PM
$MYNZ soon approved in us...and then booom 100$
0 · Reply
BioTuesdays
BioTuesdays Aug. 13 at 2:03 PM
$MYNZ has announced that its non-invasive colorectal cancer (CRC) screening test—ColoAlert—has been registered and approved for distribution by the Swiss regulatory and supervisory authority, Swissmedic. https://biotuesdays.com/2025/08/13/swissmedic-grants-mainz-approval-to-market-coloalert/
0 · Reply
Orlandotrader
Orlandotrader Aug. 13 at 12:36 PM
$MYNZ Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
0 · Reply
Tbio64
Tbio64 Aug. 13 at 12:21 PM
$MYNZ news
0 · Reply
twixbarrtwits
twixbarrtwits Aug. 13 at 12:17 PM
$MYNZ
0 · Reply
1KEI
1KEI Aug. 12 at 10:17 AM
$MYNZ
0 · Reply
Halford
Halford Aug. 11 at 4:16 PM
$MYNZ be careful
0 · Reply
Orlandotrader
Orlandotrader Aug. 5 at 3:36 PM
$MYNZ Back to 2$ area for September Early Read on Clinical Trial. Results will Moon This.
0 · Reply
peterb030
peterb030 Aug. 5 at 12:40 PM
$MYNZ funny
0 · Reply
Skypier2
Skypier2 Aug. 5 at 10:35 AM
$MYNZ No doubt
1 · Reply
Bleachedsmiles
Bleachedsmiles Aug. 4 at 2:36 PM
$MYNZ why would they even start diluting at this price range when they’ve apparently just started government funding? They know it will just tank the stock further …almost as if they want another RS Time to announce yet another partnership
1 · Reply
Righon23420
Righon23420 Aug. 4 at 1:22 PM
$MYNZ up from here!
0 · Reply
XtremeBullz
XtremeBullz Aug. 4 at 9:34 AM
$LUMN $PSKY $BTCM $MYNZ '
1 · Reply
peterb030
peterb030 Aug. 3 at 2:31 PM
$MYNZ 1.36:40+0.034 $ cents
0 · Reply